Aclaris Therapeutics logo

Aclaris Therapeutics Share Price Today (NASDAQ: ACRS)

Aclaris Therapeutics share price is $1.34 & ₹114.60 as on 21 May 2025, 20.27 hrs IST

$1.34

-0.01

(-0.74%)

Live

View live Aclaris Therapeutics share price in Dollar and Rupees. Guide to invest in Aclaris Therapeutics stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Aclaris Therapeutics, along with analyst recommendations, forecasts, and comprehensive financials.

Aclaris Therapeutics share price movements

  • Today's Low: $1.32
    Today's High: $1.37

    Day's Volatility :3.65%

  • 52 Weeks Low: $0.95
    52 Weeks High: $5.17

    52 Weeks Volatility :81.6%

Aclaris Therapeutics (ACRS) Returns

PeriodAclaris Therapeutics IncSector (Health Care)Index (Russel 2000)
3 Months
-41.34%
-8.0%
0.0%
6 Months
-65.78%
-6.4%
0.0%
1 Year
14.83%
-7.8%
0.0%
3 Years
-88.94%
3.8%
-0.2%

Aclaris Therapeutics (ACRS) Key Statistics

in dollars & INR

Previous Close
$1.35
Open
$1.29
Today's High
$1.37
Today's Low
$1.32
Market Capitalization
$140.8M
Today's Volume
$487.0K
52 Week High
$5.17
52 Week Low
$0.9515
Revenue TTM
$17.8M
EBITDA
$-53.9M
Earnings Per Share (EPS)
$-1.59
Profit Margin
0.0%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-84.46%

How to invest in Aclaris Therapeutics Stock (ACRS) from India?

It is very easy for Indian residents to invest directly in Aclaris Therapeutics from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Aclaris Therapeutics stock in both Indian Rupees (INR) and US Dollars (USD). Search for Aclaris Therapeutics or ACRS on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Aclaris Therapeutics or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Aclaris Therapeutics shares which would translate to 0.638 fractional shares of Aclaris Therapeutics as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India , including recognised companies like Aclaris Therapeutics, in just a few clicks!

Returns in Aclaris Therapeutics (ACRS) for Indian investors in Rupees

The Aclaris Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Aclaris Therapeutics investment value today

Current value as on today

₹1,16,242

Returns

₹16,242

(+16.24%)

Returns from Aclaris Therapeutics Stock

₹13,559 (+13.56%)

Dollar Returns

₹2,682 (+2.68%)

Indian investors sentiment towards Aclaris Therapeutics (ACRS)

-25%

Period: Apr 20, 2025 to May 20, 2025. Change in 30 Days versus previous period

Search interest for Aclaris Therapeutics Stock from India on INDmoney has decreased by -25% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Aclaris Therapeutics

  • BML Capital Management LLC

    13.16%

  • Adage Capital Partners Gp LLC

    8.89%

  • Vivo Capital, LLC

    8.21%

  • Rock Springs Capital Management LP

    5.73%

  • Vanguard Group Inc

    4.59%

  • RA Capital Management, LLC

    4.31%

Analyst Recommendation on Aclaris Therapeutics

Rating
Trend

Hold

    40%Buy

    60%Hold

    0%Sell

Based on 15 Wall street analysts offering stock ratings for Aclaris Therapeutics(by analysts ranked 0 to 5 stars)

Analyst Forecast on Aclaris Therapeutics Stock (ACRS)

What analysts predicted

Upside of 511.94%

Target:

$8.20

Current:

$1.34

Insights on Aclaris Therapeutics Stock (Ticker Symbol: ACRS)

  • Price Movement

    In the last 7 days, ACRS stock has moved up by 14.8%
  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 9.21M → 1.45M (in $), with an average decrease of 84.2% per quarter
  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -96.55M → -15.08M (in $), with an average increase of 540.1% per quarter
  • ACRS vs ALNY (1 yr)

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 95.0% return, outperforming this stock by 80.2%
  • ACRS vs ALNY (3 yr)

    In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 120.6% return, outperforming this stock by 209.4%
  • Price to Sales

    ForACRS every $1 of sales, investors are willing to pay $6.9, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $16.0 for every $1 of sales.

Aclaris Therapeutics Technicals Summary

Sell

Neutral

Buy

Aclaris Therapeutics is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Aclaris Therapeutics (ACRS) Vs Peers

Returns
Ratio's
Overview
Company Name1 Month6 Month1 Year3 Years5 Years
Aclaris Therapeutics Inc logo
19.91%
-65.78%
14.83%
-88.94%
10.16%
Regeneron Pharmaceuticals, Inc. logo
9.48%
-17.3%
-38.15%
-9.85%
7.87%
Beone Medicines Ltd logo
2.89%
21.41%
40.9%
74.48%
48.22%
Vertex Pharmaceuticals Incorporated logo
-6.28%
-0.82%
1.25%
66.77%
57.05%
Alnylam Pharmaceuticals, Inc. logo
25.34%
17.26%
94.99%
125.14%
107.61%

About Aclaris Therapeutics

Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. Its Contract Research segment provides laboratory services. The company also develops ATI-1777, a soft JAK 1/3 inhibitor in Phase 2b trial for the treatment of atopic dermatitis and other dermatologic conditions; Bosakitug (ATI-045), an anti-TSLP monoclonal antibody in Phase 2a trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; Zunsemetinib (ATI-450), a mitogen-activated protein kinase-activated protein kinase 2 inhibitor under Phase 1b/2 trials for the treatment of metastatic breast cancer and pancreatic ductal adenocarcinoma; and ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in preclinical stage to treat various atopic, immunologic, and respiratory diseases, as well as an ITK selective inhibitor candidate for the treatment of autoimmune diseases. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
Organization
Aclaris Therapeutics
Employees
61
CEO
Dr. Neal S. Walker D.O., M.D.
Industry
Health Technology

Management People of Aclaris Therapeutics

NameTitle
Dr. Neal S. Walker D.O., M.D.
Co-Founder, CEO & Chairman
Dr. Hugh M. Davis Ph.D.
President, COO & Director
Mr. Kevin Balthaser
Chief Financial Officer
Dr. Joseph Monahan Ph.D.
Chief Scientific Officer
Mr. William C. Roberts
Senior VP of Corporate Communications & Investor Relations
Mr. Matthew Rothman J.D.
General Counsel & Corporate Secretary
Dr. Jon Jacobsen Ph.D.
Senior Vice President of Chemistry
Mr. James Loerop
Chief Business Officer
Mr. Steve Tucker
Executive Vice President of Project Leadership
Mr. Ajay Aggarwal M.B.A., M.D.
Senior Vice President of Clinical Development

Important FAQs about investing in ACRS Stock from India :

Can Indians buy Aclaris Therapeutics shares?

Yes, Indians can invest in the Aclaris Therapeutics (ACRS) from India.

With INDmoney, you can buy Aclaris Therapeutics at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy Aclaris Therapeutics at zero transaction cost.

How can I buy Aclaris Therapeutics shares from India?

It is very easy to buy Aclaris Therapeutics from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Aclaris Therapeutics (ACRS) be purchased?

Yes, you can buy fractional shares of Aclaris Therapeutics with INDmoney app.

What are the documents required to start investing in Aclaris Therapeutics stocks?

To start investing in Aclaris Therapeutics, You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What is Aclaris Therapeutics share price today?

Aclaris Therapeutics share price today stands at $1.34, Open: $1.29 ; Previous Close: $1.35 ; High: $1.37 ; Low: $1.32 ; 52 Week High: $5.17 ; 52 Week Low: $0.95.

The stock opens at $1.29, after a previous close of $1.35. The stock reached a daily high of $1.37 and a low of $1.32, with a 52-week high of $5.17 and a 52-week low of $0.95.

What are today’s High and Low prices of Aclaris Therapeutics Stock (ACRS)?

Today’s highest price of Aclaris Therapeutics (ACRS) is $1.37.

Today’s lowest price of Aclaris Therapeutics (ACRS) is $1.32.

What is the 52 Week High and Low Range of Aclaris Therapeutics Stock (ACRS)?

  • 52 Week High

    $5.17

  • 52 Week Low

    $0.95

What are the historical returns of Aclaris Therapeutics (ACRS)?

  • 1 Month Returns

    19.91%

  • 3 Months Returns

    -65.78%

  • 1 Year Returns

    14.83%

  • 5 Years Returns

    10.16%

What is today's market capitalisation of Aclaris Therapeutics?

Today's market capitalisation of Aclaris Therapeutics ACRS is 140.8M

Who is the Chief Executive Officer (CEO) of Aclaris Therapeutics ?

Dr. Neal S. Walker D.O., M.D. is the current Chief Executive Officer (CEO) of Aclaris Therapeutics.